- Conditions: Acquired Immunodeficiency Syndrome; HIV Infections
Interventions: Drug: darunavir/cobicistat/emtricitabine/GS-7340; Drug: darunavir + cobicistat + emtricitabine/tenofovir df
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified April 2012 - Condition: HIV Infection
Interventions: Drug: Maraviroc; Drug: Emtricitabine; Drug: Tenofovir disoproxil fumarate; Other: Maraviroc placebo; Other: Emtricitabine placebo; Other: Tenofovir disoproxil fumarate placebo
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID); HIV Prevention Trials Network
Not yet recruiting - verified May 2012 - Condition: HIV Infections
Intervention: Drug: Etravirine (ETR)
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified May 2012 - Conditions: Acquired Immunodeficiency Syndrome; HIV Infections
Interventions: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir df; Drug: NNRTI plus FTC/TDF
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified March 2012 - Condition: HIV-1 Infection
Interventions: Drug: BMS-986001; Drug: BMS-986001; Drug: BMS-986001; Drug: Placebo matching with BMS-986001; Drug: Efavirenz; Drug: Lamivudine; Drug: Tenofovir
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified December 2011 - Conditions: HIV Infections; Hepatitis C
Interventions: Drug: Pegylated-Interferon Alfa 2b (PEG-IFN); Drug: Ribavirin (RBV); Drug: Boceprevir (BOC)
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified May 2012 - Conditions: HIV; Sexual Risk; Sexually Transmitted Diseases; Substance Abuse; Violence; Victimization
Interventions: Behavioral: Test, Treat, Retain(TTR) + Women's Health CoOp (WHC); Biological: Test, Treat, Retain(TTR) only
Sponsors: RTI International; RTI International; University of North Carolina, Chapel Hill
Not yet recruiting - verified December 2011 - Conditions: Acquired Immunodeficiency Syndrome; HIV Infections
Interventions: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir df; Drug: ritonavir-boosted protease inhibitor plus Truvada
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified March 2012 - Condition: HIV-1 Infection
Interventions: Drug: Pravastatin sodium; Drug: Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate; Drug: Pravastatin sodium
Sponsors: AIDS Clinical Trials Group; AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified January 2012 - Condition: Hepatitis C, Genotype 1
Interventions: Drug: BMS-790052 (Daclatasvir); Drug: Ribavirin; Drug: Peg-Interferon alfa 2a
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified April 2012 - Condition: Hepatitis C
Interventions: Drug: Telaprevir; Drug: Ribavirin; Biological: peginterferon alfa-2a
Sponsors: Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals Incorporated
Recruiting - verified May 2012 - Condition: HIV Infections
Interventions: Biological: Quadrivalent HPV Vaccine; Biological: Placebo Vaccine
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2012 - Condition: HIV-1 Infection
Intervention: Drug: Rifaximin
Sponsors: AIDS Clinical Trials Group; AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified November 2011 - Conditions: Acquired Immunodeficiency Syndrome; HIV Infections
Interventions: Drug: Cobicistat; Drug: Darunavir
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified October 2011 - Condition: Healthy
Intervention: Drug: dolutegravir
Sponsors: University of North Carolina, Chapel Hill; University of North Carolina, Chapel Hill; GlaxoSmithKline
Recruiting - verified December 2011 - Conditions: Tuberculosis; HIV Infections
Interventions: Drug: Rifapentine (RPT); Drug: Isoniazid (INH); Dietary Supplement: Pyridoxine (Vitamin B6)
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified May 2012 - Condition: HIV-1 Infection
Interventions: Drug: Atripla; Drug: Calcium Carbonate; Drug: Vitamin D3; Drug: Placebo for calcium carbonate; Drug: Placebo for vitamin D3
Sponsors: AIDS Clinical Trials Group; AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified February 2012 - Condition: HIV-1 Infection
Interventions: Drug: Darunavir; Drug: Ritonavir; Drug: Tenofovir disoproxil fumarate; Drug: Emtricitabine; Drug: Placebo for Tenofovir disoproxil fumarate; Drug: Placebo for Maraviroc
Sponsors: AIDS Clinical Trials Group; AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified September 2011 - Condition: Hepatitis C, Chronic
Interventions: Drug: BI201335; Drug: BI201335 24W; Drug: PegIFN/RBV; Drug: PegIFN/RBV
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Condition: Human Immunodeficiency Virus-1
Interventions: Drug: BMS-663068; Drug: BMS-663068; Drug: BMS-663068; Drug: BMS-663068; Drug: Raltegravir; Drug: Raltegravir; Drug: Tenofovir; Drug: Tenofovir; Drug: Ritonavir; Drug: Atazanavir
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified February 2012 - Feasibility of a Stigma Reduction Intervention for Human Immunodeficiency Virus (HIV)-Infected WomenConditions: Human Immunodeficiency Virus (HIV); Self-efficacy; Self-esteem
Intervention: Behavioral: Ipod video
Sponsors: Duke University; Duke University; National Institute of Nursing Research (NINR)
Not yet recruiting - verified July 2011 - Conditions: Depression; HIV
Intervention: Other: Measurement-Based Care collaborative depression management
Sponsors: Duke University; Duke University; National Institute of Mental Health (NIMH); University of North Carolina, Chapel Hill; University of Alabama at Birmingham
Recruiting - verified June 2011 - Conditions: Acquired Immunodeficiency Syndrome; HIV Infections
Interventions: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir DF; Drug: cobicistat and atazanavir or cobicistat and darunavir
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified March 2012 - Condition: HIV-1
Interventions: Drug: Maraviroc; Drug: Emtricitabine/tenofovir
Sponsors: ViiV Healthcare; ViiV Healthcare; Pfizer
Recruiting - verified May 2012 - Condition: HIV-1 Infection
Interventions: Drug: Cenicriviroc 100 mg; Drug: Cenicriviroc 200 mg + Truvada; Drug: Sustiva + Truvada
Sponsors: Tobira Therapeutics, Inc.; Tobira Therapeutics, Inc.
Recruiting - verified October 2011 - Condition: HIV Disease
Interventions: Drug: HAART regimen; Drug: 3TC or FTC monotherapy
Sponsors: International Maternal Pediatric Adolescent AIDS Clinical Trials Group; International Maternal Pediatric Adolescent AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified May 2012 - Condition: Infection, Human Immunodeficiency Virus
Intervention: Drug: dolutegravir
Sponsors: ViiV Healthcare; ViiV Healthcare; Shionogi; GlaxoSmithKline
Recruiting - verified February 2012 - Conditions: HIV Coinfection; Hepatitis C; Hepatitis B; Hepatotoxicity
Interventions: Drug: Maraviroc; Drug: Placebo
Sponsors: ViiV Healthcare; ViiV Healthcare; Pfizer
Recruiting - verified May 2012 - The Effect of Vorinostat on HIV RNA Expression in the Resting CD4+ T Cells of HIV+ Pts on Stable ARTCondition: HIV-1 Infection
Intervention: Drug: Vorinostat
Sponsors: University of North Carolina, Chapel Hill; University of North Carolina, Chapel Hill; National Institutes of Health (NIH); Merck; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified November 2011 - Condition: HIV Infections
Interventions: Drug: GSK1349572 tablet formulation; Drug: GSK1349572 pediatric formulation
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2012 - Condition: HIV-1 Infection
Intervention: Drug: depo-medroxyprogesterone acetate
Sponsors: AIDS Clinical Trials Group; AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified September 2011 - Condition: HIV Infection
Intervention: Drug: Lopinavir/ritonavir (LPV/r)
Sponsors: International Maternal Pediatric Adolescent AIDS Clinical Trials Group; International Maternal Pediatric Adolescent AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Abbott
Recruiting - verified May 2012 - Condition: Contraception
Intervention: Drug: one of 5 products
Sponsors: FHI 360; FHI 360; National Institutes of Health (NIH)
Recruiting - verified April 2012 - Condition: HIV-1 Infection
Intervention: Drug: Rilpivirine
Sponsors: Janssen R&D Ireland; Janssen R&D Ireland
Recruiting - verified April 2012 - Condition: HIV-1 Infection
Interventions: Drug: atorvastatin; Drug: atorvastatin
Sponsors: AIDS Clinical Trials Group; AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID); Pfizer
Recruiting - verified September 2011 - Condition: ADHD
Intervention:
Sponsors: International Maternal Pediatric Adolescent AIDS Clinical Trials Group; International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Recruiting - verified May 2012 - Condition: Human Immunodeficiency Virus
Interventions: Drug: tenofovir/emtricitabine/efavirenz (TDF/FTC/EFV); Drug: tenofovir/emtricitabine (TDF/FTC); Drug: Atazanavir (ATV); Drug: Ritonavir; Procedure: Phlebotomy
Sponsors: University of North Carolina, Chapel Hill; University of North Carolina, Chapel Hill; Society of Infectious Diseases Pharmacists; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified November 2011 - Condition: HIV
Intervention: Drug: Lopinavir/ritonavir
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2012 - Conditions: Birth Defects; Infection, Human Immunodeficiency Virus
Intervention: Drug: Any Antiretroviral Therapy
Sponsors: ViiV Healthcare; ViiV Healthcare; GlaxoSmithKline
Recruiting - verified February 2012 - Condition: HIV Infection
Interventions: Biological: AGS-004; Biological: Placebo
Sponsors: Argos Therapeutics; Argos Therapeutics
Recruiting - verified November 2011 - Condition: HIV Infections
Intervention:
Sponsors: International Maternal Pediatric Adolescent AIDS Clinical Trials Group; International Maternal Pediatric Adolescent AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2012 - Condition: HIV Infections
Intervention:
Sponsors: AIDS Clinical Trials Group; AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified October 2011 - Condition: HIV Infections
Interventions: Behavioral: Enhanced nursing telephone support; Behavioral: Standard care
Sponsors: AIDS Clinical Trials Group; AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified September 2011 - Condition: HIV Infections
Interventions: Drug: Raltegravir (RAL); Drug: Atazanavir (ATV); Drug: Ritonavir (RTV); Drug: Tenofovir (TDF); Drug: Etravirine (ETV); Drug: Darunavir (DRV); Drug: Maraviroc (MVC); Drug: Lopinavir/ritonavir (LPV/r)
Sponsors: International Maternal Pediatric Adolescent AIDS Clinical Trials Group; International Maternal Pediatric Adolescent AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2012 - Condition: HIV Infections
Intervention: Drug: Etravirine (Intelence)
Sponsors: University of North Carolina, Chapel Hill; University of North Carolina, Chapel Hill; Janssen Pharmaceuticals
Recruiting - verified December 2011 - Condition: HIV Infections
Intervention:
Sponsors: AIDS Clinical Trials Group; AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified February 2012 - Condition: HIV Infections
Intervention: Drug: Highly active antiretroviral therapy (HAART)
Sponsors: International Maternal Pediatric Adolescent AIDS Clinical Trials Group; International Maternal Pediatric Adolescent AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2012 - Conditions: Acute HIV Infection; HIV Infections
Intervention: Drug: Atripla
Sponsors: University of North Carolina, Chapel Hill; University of North Carolina, Chapel Hill; Bristol-Myers Squibb; Gilead Sciences
Recruiting - verified December 2011 - Condition: HIV Infections
Interventions: Drug: Alendronate; Drug: Alendronate placebo; Dietary Supplement: Calcium carbonate/vitamin D
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified May 2012 - Condition: HIV Infection
Intervention: Drug: All licensed antiretroviral medications
Sponsors: University of Minnesota - Clinical and Translational Science Institute; University of Minnesota - Clinical and Translational Science Institute; National Institute of Allergy and Infectious Diseases (NIAID); Copenhagen HIV Programme (CHIP) -- Copenhagen, Denmark; Medical Research Council (MRC) Clinical Trials Unit -- London, United Kingdom; Kirby Institute; The Institute for Clinical Research at the Veterans Affairs Medical Center -- Washington, D.C., USA; French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS); German Federal Ministry of Education and Research; NEAT - European AIDS Treatment Network; National Health and Medical Research Council, Australia; National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI); National Heart, Lung, and Blood Institute (NHLBI); National Institute of Mental Health (NIMH); National Institute of Neurological Disorders and Stroke (NINDS); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); Abbott; Bristol-Myers Squibb; Gilead Sciences; GlaxoSmithKline; Merck; Tibotec Pharmaceutical Limited
Recruiting - verified April 2012 - Conditions: Acute HIV Infection; HIV Infections
Intervention: Drug: Darunavir/Ritonavir and Etravirine
Sponsors: University of North Carolina, Chapel Hill; University of North Carolina, Chapel Hill; Janssen Pharmaceuticals
Recruiting - verified December 2011 - Conditions: HIV; HIV Infections; Pregnancy
Interventions: Drug: TMC114 (darunavir); Drug: ritonavir; Drug: TMC125 (etravirine); Drug: TMC278 (rilpivirine); Drug: TMC114 (darunavir)
Sponsors: Tibotec, Inc; Tibotec, Inc; Janssen Services, LLC
Recruiting - verified May 2012 - Conditions: HIV Infections; Sexually Transmitted Infections
Interventions: Behavioral: Male Sexual Health Program; Behavioral: Focus on the Future Program
Sponsors: University of Kentucky; University of Kentucky; Louisiana State University Health Sciences Center in New Orleans; Carolinas Healthcare System
Recruiting - verified August 2011 - Condition: HIV-1
Interventions: Drug: UK-453,061 Dose 1; Drug: UK-453,061 Dose 2; Drug: Etravirine
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: HIV Infections
Interventions: Drug: Chloroquine; Drug: Placebo
Sponsors: AIDS Clinical Trials Group; AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified February 2012 - Condition: Human Immunodeficiency Virus
Interventions: Drug: Maraviroc along with an optimized background antiretroviral drug regimen; Drug: Optimized background antiretroviral drug regimen without maraviroc
Sponsors: ViiV Healthcare; ViiV Healthcare; Pfizer
Recruiting - verified May 2012 - Conditions: HIV Infections; Hyperlipidemia
Intervention: Drug: Atorvastatin
Sponsors: International Maternal Pediatric Adolescent AIDS Clinical Trials Group; International Maternal Pediatric Adolescent AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified May 2012 - Condition: HIV Infections
Intervention: Drug: ARV regimen chosen by treating physician
Sponsors: University of North Carolina, Chapel Hill; Kristine Patterson, MD; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified March 2012 - Condition: HIV Infections
Interventions: Drug: Raltegravir (MK-0518); Drug: Raltegravir (MK-0518); Drug: Raltegravir (MK-0518)
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified April 2012 - Condition: HIV Infections
Intervention: Drug: Tipranavir
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Available - verified May 2012 - Condition: HIV Infections
Intervention: Drug: Current ARV medications
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified April 2012 - Condition: HIV Infections
Intervention:
Sponsors: AIDS Clinical Trials Group; AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified January 2012 - Conditions: HIV Infections; Pregnancy Complications, Infectious
Intervention: Behavioral: Adherence assessment
Sponsors: International Maternal Pediatric Adolescent AIDS Clinical Trials Group; International Maternal Pediatric Adolescent AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified May 2012 - Condition: HIV Infections
Intervention:
Sponsors: AIDS Clinical Trials Group; AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified January 2012
 |
Join Clinical Trials in North Carolina for aids/hiv |
